Post-approval studies (Phase 4)Active Not RecruitingNCT05160922What this trial is testingCrizotinib Continuation Clinical StudyWho this might be right forNSCLCALCLIMT Pfizer 27
Testing effectiveness (Phase 2)Ended earlyNCT02465528What this trial is testingCeritinib Rare Indications Study in ALK+ TumorsWho this might be right forTumors With Aberrations in ALKAnaplastic Large Cell LymphomaInflammatory Myofibroblastic Tumor+1 more Novartis Pharmaceuticals 22
Testing effectiveness (Phase 2)Looking for participantsNCT04925609What this trial is testingBrigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid TumorsWho this might be right forAnaplastic Large Cell Lymphoma, ALK-PositiveInflammatory Myofibroblastic TumorOther Solid Tumor Princess Maxima Center for Pediatric Oncology 65
Not applicableStudy completedNCT02971176What this trial is testingLow-dose Protocol for Computed Tomography-guided Lung BiopsyWho this might be right forLung Cancer, AdenocarcinomaLung Inflammatory Pseudotumor Xuzhou Central Hospital 280
Testing effectiveness (Phase 2)Looking for participantsNCT06239272What this trial is testingNRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)Who this might be right forAdipocytic NeoplasmLiposarcomaAtypical Fibroxanthoma+6 more St. Jude Children's Research Hospital 139
Not applicableUnknownNCT04572594What this trial is testingMolecular Profiling and Molecular Labeling of Inflammatory Myofibroblastic TumorWho this might be right forInflammatory Myofibroblatic Tumor Sun Yat-sen University 29
Testing effectiveness (Phase 2)WithdrawnNCT04260009What this trial is testingPharmacokinetics, Safety, and Efficacy of Brigatinib Monotherapy in Pediatric and Young Adult Participants With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid TumorsWho this might be right forAnaplastic Lymphoma Kinase Positive (ALK +) Anaplastic Large Cell LymphomaInflammatory Myofibroblastic TumorsSolid Tumors Takeda
Large-scale testing (Phase 3)Active Not RecruitingNCT02180867What this trial is testingRadiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by SurgeryWho this might be right forAlveolar Soft Part SarcomaAngiomatoid Fibrous HistiocytomaAtypical Fibroxanthoma+33 more National Cancer Institute (NCI) 140
Not applicableAvailableNCT05100134What this trial is testingManaged Access Programs for LDK378, CeritinibWho this might be right forAnaplastic Lymphoma Kinase (ALK)- Positive TumorsNon-small Cell Lung Cancer (NSCLC) Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT01524926What this trial is testingCREATE: Cross-tumoral Phase 2 With CrizotinibWho this might be right forLocally Advanced and/or Metastatic Anaplastic Large Cell LymphomaLocally Advanced and/or Metastatic Inflammatory Myofibroblastic TumorLocally Advanced and/or Metastatic Papillary Renal Cell Carcinoma Type 1+3 more European Organisation for Research and Treatment of Cancer - EORTC 582
Early research (Phase 1)Study completedNCT01742286What this trial is testingPhase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)Who this might be right forALK-activated Tumors Novartis Pharmaceuticals 83
Not applicableNo Longer AvailableNCT03085186What this trial is testingTreatment With Crizotinib Single Patient Expanded Access IND 134375Who this might be right forInflammatory Myofibroblastic Tumour Jean M. Tersak, M.D.
Testing effectiveness (Phase 2)Study completedNCT01625234What this trial is testingPhase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung CancerWho this might be right forAdvanced Solid TumorsNon-small Cell Lung Cancer Xcovery Holdings, Inc. 131
Large-scale testing (Phase 3)UnknownNCT03874273What this trial is testingStudy of Crizotinib in Children and Adolescents With Myofibroblastic TumorsWho this might be right forInflammatory Myofibroblastic Tumor Federal Research Institute of Pediatric Hematology, Oncology and Immunology 25
Testing effectiveness (Phase 2)Looking for participantsNCT04094610What this trial is testingRepotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsWho this might be right forLocally Advanced Solid TumorsMetastatic Solid TumorsLymphoma+1 more Turning Point Therapeutics, Inc. 75